VEGF/Ang2 antibody therapy (Ambrx)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameVEGF/Ang2 antibody therapy (Ambrx)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionVascular endothelial growth factor inhibitorsAngiopoietin-2 inhibitors

TargetsVascular endothelial growth factorAngiopoietin-2

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmbrx Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmbrx Inc

Active IndicationsN/A

Inactive IndicationsMacular Degeneration

ATC CodeN/A